Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation

Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology.  PMID: 27400728  DOI: 10.1080/00365521.2016.1205128

Highlight from this Publication

“The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action, rather than persisting for several months.”

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use.

Health Canada License: 80726